High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway

Clinical Cancer Research

Volumn 18, Issue 5, 2012, Pages 1374-1385

  Yoshihara, Kosuke ^a   Tsunoda, Tatsuhiko ^b   Shigemizu, Daichi ^b   Fujiwara, Hiroyuki ^d   Hatae, Masayuki ^e   Fujiwara, Hisaya ^f   Masuzaki, Hideaki ^g   Katabuchi, Hidetaka ^h   Kawakami, Yosuke ⁱ   Okamoto, Aikou ^j   Nogawa, Takayoshi ⁱ   Matsumura, Noriomi ⁿ   Udagawa, Yasuhiro ^o   Saito, Tsuyoshi ^p   Itamochi, Hiroaki ^q   Takano, Masashi ^r   Miyagi, Etsuko ^c   Sudo, Tamotsu ^s   Ushijima, Kimio ^t   Iwase, Haruko ^k   Seki, Hiroyuki ^u   Terao, Yasuhisa ^l   Enomoto, Takayuki ^v   Mikami, Mikio ^w   Akazawa, Kohei ^a   Tsuda, Hitoshi ^m   Moriya, Takuya ^x   Tajima, Atsushi ^y   Inoue, Ituro ^z   Tanaka, Kenichi ^a   more..

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b RIKEN YOKOHAMA INSTITUTE   (Japan)

^c YOKOHAMA CITY UNIVERSITY HOSPITAL   (Japan)

^d JICHI MEDICAL UNIVERSITY   (Japan)

^e Kagoshima City Hospital   (Japan)

^f HIROSHIMA UNIVERSITY   (Japan)

^g NAGASAKI UNIVERSITY   (Japan)

^h KUMAMOTO UNIVERSITY   (Japan)

ⁱ NATIONAL HOSPITAL ORGANIZATION   (Japan)

^j JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k CANCER INSTITUTE HOSPITAL   (Japan)

^l JUNTENDO UNIVERSITY   (Japan)

^m NATIONAL CANCER CENTER HOSPITAL   (Japan)

ⁿ KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^o FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^p SAPPORO MEDICAL UNIVERSITY   (Japan)

^q TOTTORI UNIVERSITY   (Japan)

^r NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^s HYOGO CANCER CENTER   (Japan)

^t KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^u SAITAMA MEDICAL UNIVERSITY   (Japan)

^v OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^w TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^x KAWASAKI MEDICAL SCHOOL   (Japan)

^y UNIVERSITY OF TOKUSHIMA   (Japan)

^z NATIONAL INSTITUTE OF GENETICS   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1;

ADULT; ADVANCED CANCER; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION SIGNATURE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE GENE; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PATIENT CODING; PATIENT IDENTIFICATION; PRIORITY JOURNAL; RISK ASSESSMENT;

AGED; ANTIGEN PRESENTATION; CLUSTER ANALYSIS; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

EID: 84863247567     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2725     Document Type: Article

References (43)

1. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-29.
2. Kurman RJ, Visvanathan K, Roden R, Wu TC, ShihIe M. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 2008;198:351-6. (Pubitemid 351451941)
3. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 2008;26: 5284-93.
4. Bowtell DD. The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 2010;10:803-8.
5. Winter WE 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:3621-7. (Pubitemid 47372600)
6. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009;115:1234-44.
7. Dowsett M, Dunbier AK. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 2008;14:8019-26.
8. Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol 2010;220: 263-80.
9. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010;221:49-56.
10. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
11. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008;14:5198-208.
12. Bonome T, Levine DA, Shih J, Randonovich M, Pise-Masison CA, Bogomolniy F, et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res 2008;68: 5478-86.
13. Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 2007;25: 517-25. (Pubitemid 350002958)
14. Majewski IJ, Bernards R. Taming the dragon: genomic biomarkers to individualize the treatment of cancer. Nat Med 2011;17:304-12.
15. Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. J Epidemiol Biostat 2001;6:107-38. (Pubitemid 33134081)
16. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al.: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
17. Tavassoli FA, Devilee P. World Health Organization Classification of Tumors. Pathology & Genetics. Tumors of the breast and female genital organs. Lyon (France): IARC Press; 2003. p. 117-45.
18. Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 2000;19:7-15. (Pubitemid 30010638)
19. Yoshihara K, Tajima A, Yahata T, Kodama S, Fujiwara H, Suzuki M, et al. Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. PLoS One 2010;5:e9615.
20. Glaab E, Garibaldi J, Krasnogor N. ArrayMining: a modular web-application for microarray analysis combining ensemble and consensus methods with cross-study normalization. BMC Bioinformatics 2009;10:358.
21. Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, Regitnig P, et al. Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol 2010;28:4111-9.
22. Simon N, Friedman J, Hastie T. Regularization paths for Cox's proportional hazards model via coordinate descent. J Stat Softw 2010;39: 1-22.
23. R Development Core Team. R: A language and environment for statistical computing. 2011
24. Brunet JP, Tamayo P, Golub TR, Mesirov JP. Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci U S A 2004;101:4164-9. (Pubitemid 38405900)
25. Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Ann Stat 2001;29:1165-88. (Pubitemid 33575263)
26. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: Aknowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50. (Pubitemid 41528093)
27. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B 1995;57:289-300.
28. Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, et al. HLAclass I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res 2008;14:3372-9.
29. Leffers N, Fehrmann RS, Gooden MJ, Schulze UR, Ten Hoor KA, Hollema H, et al. Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer. Br J Cancer 2010;103:685-92.
30. Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011;105:93-103.
31. Leffers N, Daemen T, Helfrich W, Boezen HM, Cohlen BJ, Melief K, et al. Antigen-specific active immunotherapy for ovarian cancer. Cochrane Database Syst Rev 2010;1:CD007287.
32. Kandalaft LE, Powell DJ Jr, Singh N, Coukos G. Immunotherapy for ovarian cancer: what's next? J Clin Oncol 2011;29:925-33.
33. Rolland P, Deen S, Scott I, Durrant L, Spendlove I. Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer. Clin Cancer Res 2007;13:3591-6. (Pubitemid 46955120)
34. Shehata M, Mukherjee A, Deen S, Al-Attar A, Durrant LG, Chan S. Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy. Br J Cancer 2009;101:1321-8.
35. Tanaka K, Hayashi H, Hamada C, Khoury G, Jay G. Expression of major histocompatibility complex class I antigens as a strategy for the potentiation of immune recognition of tumor cells. Proc Natl Acad Sci U S A 1986;83:8723-7. (Pubitemid 17194938)
36. Garrido F, Cabrera T, Aptsiauri N. "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer 2010;127:249-56.
37. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002;3: 999-1005. (Pubitemid 35363649)
38. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006;6:836-48. (Pubitemid 44631652)
39. Khan AN, Gregorie CJ, Tomasi TB. Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol Immunother 2008;57: 647-54.
40. Setiadi AF, Omilusik K, David MD, Seipp RP, Hartikainen J, Gopaul R, et al. Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. Cancer Res 2008;68:9601-7.
41. Kitamura H, Torigoe T, Asanuma H, Honma I, Sato N, Tsukamoto T. Down-regulation of HLA class I antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition. J Urol 2007;178: 692-6. (Pubitemid 47030489)
42. Chobanian NH, Greenberg VL, Gass JM, Desimone CP, Van Nagell JR, Zimmer SG. Histone deacetylase inhibitors enhance paclitaxelinduced cell death in ovarian cancer cell lines independent of p53 status. Anticancer Res 2004;24:539-45. (Pubitemid 38624987)
43. Qian X, LaRochelle WJ, Ara G, Wu F, Petersen KD, Thougaard A, et al. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther 2006;5: 2086-95. (Pubitemid 44336581)